PDK1 and breast carcinoma: In addition to these, OSU-03012, a derivative of celecoxib, a cyclooxygenase-2 (COX2) inhibitor, which accounts for PDK1 but not COX2 inhibition [46], managed to sensitize breast cancer cell lines to tamoxifen therapy independently of their ER status and the ER downstream pathway.